BACKGROUND: Whether patient navigation improves outcomes for patients with comorbidities is unknown. The aims of this study were to determine the effect of comorbidities on the time to diagnostic resolution after an abnormal cancer screening test and to examine whether patient navigation improves the timeliness and likelihood of diagnostic resolution for patients with comorbidities in comparison with no navigation. METHODS: A secondary analysis of comorbidity data collected by Patient Navigation Research Program sites using the Charlson Comorbidity Index (CCI) was conducted. The participants were 6,349 patients with abnormal breast, cervical, colon, or prostate cancer screening tests between 2007 and 2011. The intervention was patient navigation or usual care. The CCI data were highly skewed across projects and cancer sites, and the CCI scores were categorized as 0 (CCI score of 0 or no comorbidities identified; 76% of cases); 1 (CCI score of 1; 16% of cases), or 2 (CCI score 2; 8% of cases). Separate adjusted hazard ratios for each site and cancer type were obtained, and then they were pooled with a meta-analysis random effects methodology. RESULTS: Patients with a CCI score 2 had delayed diagnostic resolution after an abnormal cancer screening test in comparison with those with no comorbidities. Patient navigation reduced delays in diagnostic resolution, with the greatest benefits seen for those with a CCI score 2. CONCLUSIONS: Persons with a CCI score 2 experienced significant delays in timely diagnostic care in comparison with patients without comorbidities. Patient navigation was effective in reducing delays in diagnostic resolution among those with CCI scores > 1. Cancer 2017;123:312-8.
INTRODUCTION
A relation between the severity of comorbidities and outcomes after a cancer diagnosis has been found for several cancer types, including breast, prostate, and colon cancers. [1] [2] [3] [4] One possible contributor to poor cancer outcomes for those with comorbidities is the delay in achieving a diagnosis or treatment due to the need to manage and address other comorbid conditions. Concurrent comorbidities have the greatest impact on survival for patients with cancers for which the overall mortality is lower; this suggests that comorbidities have a negative impact for those cancers for which timely treatment may be of the greatest benefit. 5 Whether interventions that increase timely completion of the screening, diagnostic evaluation, or treatment of cancer will improve outcomes for patients with comorbidities is unknown.
Patient navigation has been shown to be effective in reducing delays and loss to follow-up after an abnormal breast, cervical, or colorectal cancer screening test in the Patient Navigation Research Program (PNRP). [6] [7] [8] [9] [10] [11] [12] Patient navigation focuses on identifying and reducing barriers to care that patients experience as they navigate the health care system. Nothing is known about whether patient navigation will improve the timeliness of diagnostic care after an abnormal cancer screening among patients with comorbidities. It is possible that individuals with comorbidities may have longer times to diagnostic resolution after an abnormal cancer screening test than those with no comorbidities and that patient navigation could support patients who require coordination of diagnostic testing with chronic disease management.
MATERIALS AND METHODS

Objective
The purpose of our study was to analyze the effects of comorbidities, defined as the coexistence of chronic diseases and measured with the Charlson Comorbidity Index (CCI), on the time to diagnostic resolution after an abnormal cancer screening with data from the PNRP. We examined whether patient navigation was effective in improving the timeliness and likelihood of diagnostic resolution for patients in comparison with participants who did not receive patient navigation. Two main hypotheses were explored: 1) patients with comorbidities of increased severity would have longer times to diagnostic resolution (and a smaller proportion would be resolved) in comparison with patients with no or less severe comorbidities, and 2) navigation would significantly reduce the time to diagnostic resolution (or increase the percentage resolved) among persons with more severe comorbidities, and this effect would be greater for them than patients with less severe or no comorbidities (interaction effect).
Design
We conducted a secondary analysis of data from 4 of the 10 PNRP sites (Boston, Denver, San Antonio, and Tampa) that collected comorbidity data from PNRP participants. We used the CCI, a valid prognostic indicator for 1-year mortality that measures and classifies comorbidities. 13, 14 The PNRP was a cooperative effort of 10 US health care organizations serving primarily medically underserved populations 6, 7 ; it was conducted between 2007 and 2011 and included more than 10,500 participants. The PNRP investigated whether patient navigation reduced the time to diagnostic resolution after an abnormal screening for breast, cervical, colorectal, or prostate cancer. Participants were censored at 365 days if they did not achieve resolution. Each site allocated patients to either a usual-care arm (the control arm) or a patient-navigation arm. The institutional review board of each organization approved the research.
Patient navigators assisted patients in identifying barriers to care, developed strategies to address these barriers, and tracked participants through the steps in their medical evaluation. The patient navigators focused on supporting participants to a timely diagnostic resolution. Navigation was initiated after a clinician informed the participant of the abnormal test result. Contacts between patient navigators and patients were face-to-face interactions as well as telephone and mail contact. Patient navigators worked with families, health care providers, and social service agencies to identify resources to address barriers to care. Patient navigators identified barriers from a prespecified list of 21 barriers and then coded activities that they undertook to ameliorate these barriers. Examples of barriers to care and associated navigation activities included financial barriers and arranging financial support, language barriers and arranging for interpreter services, and a lack of social support and linking patients to community resources. 15, 16 Patient navigators were specifically trained to support the coordination and scheduling of needed appointments, including the optimization of care for comorbid conditions. Each site hired patient navigators with a minimum of a high school diploma. Navigators participated in annual national training and webinars to standardize the intervention and were assessed for national core competencies twice annually with a standardized checklist. 17 
Main Measures
Four PNRP sites collected comorbidity data for both treatment and control groups; this yielded a total of 6349 cases. Two sites (Boston and Denver) used the CCI macro code with International Classification of Diseases, Ninth Revision, Clinical Modification. This program reads through the diagnosis codes of patient records and identifies whether records belong to 1 or more different CCI groups. 18 Two sites (San Antonio and Tampa) collected comorbidity data from patient self-report and medical records. 11, 12 Cases that were missing a CCI score were excluded.
A prior diagnosis of leukemia, lymphoma, or a metastatic solid tumor was an exclusion criterion for inclusion in the trial, so these were, therefore, not included in the calculation of CCI scores. Patients with all other comorbidities that make up the CCI score were included. Because the CCI score data were highly skewed (a consistent finding across projects and across cancer screening sites), the weighted CCI scores were categorized as 0 (CCI score of 0 or no comorbidities identified; 76% of cases), 1 (CCI score of 1; 16% of cases), or 2 (CCI score 2; 8% of cases).
Our primary measure of interest was the time to diagnostic resolution, which was defined as the time from the date of the initial screening abnormality to the date when the final definitive diagnostic test or evaluation was completed. Participants without resolution of their screening abnormality were censored at 365 days. According to our prior work, 7 our time-to-event analyses violated rules of proportionality across the 1-year timeframe. To address this, we divided our time frame and examined 2 timeframes to assess the percentage of patients achieving resolution: within 90 days as an indicator of early or timely resolution and within 365 days as the end of the followup period for the PNRP. Separate logistic regression analyses were performed for the 90-and 365-day time periods with the same covariates used in the Cox regressions. The adjusted odds ratios of achieving diagnostic resolution were obtained through comparisons of patients with categorized CCI scores of 1 versus 0 and 2 versus 0. For each time period, a random effects meta-analysis was performed separately for comorbidity scores of 1 and comorbidity scores > 1.
Analysis
Cox proportional hazards regression was conducted for all PNRP center/cancer site combinations to obtain estimates of the effect of comorbidity classification on the time to diagnostic resolution after an abnormal finding on cancer screening. Comorbidity classification was the primary variable of interest and was included as an indicator variable in the analysis. Intervention and the interaction of comorbidity classification with intervention were included in the Cox proportional hazards regressions along with the primary patient-level covariates: race/ethnicity, insurance status, age, and marital status. 19 We created a separate Cox proportional hazards regression for each site and each cancer screening type for a total of 9 regressions. From each of the 9 Cox proportional hazards regressions, an estimate of the effect of comorbidity on the time to diagnostic resolution-an adjusted hazard ratio (aHR)-was obtained. These 9 estimates were then included in a meta-analysis to obtain a pooled estimate of the effect of comorbidities on the time to resolution. An influence analysis (or sensitivity analysis) was performed: we sequentially removed the effect of each project/cancer site estimate in turn to determine whether any observed pooled effect was unduly influenced by a single project/cancer site combination.
In addition to the measure of the time to diagnostic resolution, logistic regression analyses were conducted for diagnostic resolution as a dichotomous variable. Two time points were chosen for the analysis-90 and 365 days-to capture a potential early effect of comorbidities on diagnostic resolution and a final follow-up time point of 1 year. The same covariates in the Cox proportional hazards analyses were included in the logistic regression analysis. Similarly, the 9 estimates (adjusted odds ratios) of the effect of comorbidity on diagnostic resolution were included in a meta-analysis and a subsequent influence analysis.
Lastly, data were pooled across the 4 sites that collected comorbidity data, and a subgroup analysis was performed with the pooled data to estimate the effect of patient navigation on the time to diagnostic resolution for patients with and without comorbidities RESULTS CCI scores in the PNRP data set ranged from 0 to 11 with a possible score of 25. The distribution of navigated and control patients by PNRP centers and within cancer sites was sufficient for the purposes of this analysis (Table 1) . There were 6,349 study participants: 3,134 were assigned to the usual-care arm (the control arm), and 3,215 were assigned to the navigation arm. Almost half of the participants for this analysis (48%) were from Boston, with Tampa contributing 20% of the cases and Denver and San Antonio contributing 16% each. Overall, 95% of the study participants were female, and the mean age was 43.6 years. Almost half of the study participants (47%) were Hispanic, 28% were white, and 20% were African American. Only 19% of the study participants had private health insurance, 46% had public health coverage, and 35% reported being uninsured. The majority of participants (62%) had an abnormal screening for breast cancer, 29% had an abnormal screening for cervical cancer, 7% had an abnormal screening for colorectal cancer, and 2% had an abnormal screening for prostate cancer.
Original Article
To confirm that the CCI was not a proxy measure for the number of barriers, we examined the relation of the CCI score (0, 1, or > 1) with the number of unique barriers (categorized as 0, 1, 2-3, or 4; v 2 (6) 5 6.27; P 5 .394), and we determined that these 2 variables were assessing different constructs.
Time to Diagnostic Resolution
Individual Cox proportional hazards regressions were conducted for each of the PNRP/cancer site combinations; included in each analysis were the comorbidity scores, intervention arm, interaction of the comorbidity score and the intervention arm, race/ethnicity, insurance status, age, marital status, and sex. The interaction of the comorbidity score and the intervention arm was not statistically significant (Fig. 1) . Separate meta-analyses were performed for comorbidity scores of 1 and comorbidity scores > 1 in comparison with a comorbidity score of 0 with a random effects model (Figs. 2 and 3) . 20 Among patients without navigation, the time to resolution for an abnormal cancer screening was similar for patients with a comorbidity score of 1 and patients with no reported comorbidities (combined aHR, 1.00; 95% confidence interval [CI], 0.917-1.095). For patients with a comorbidity score > 1, however, the combined aHR was 0.82 (95% CI, 0.721-0.940), and this indicated that persons with more or more severe comorbidities obtained resolution of an abnormal finding on cancer screening at a slower rate than patients with no comorbidities. The influence analysis indicated that the overall result was not unduly influenced by any 1 project/cancer type combination: the combined result remained statistically significant even with the removal of each project/cancer type combination.
We next conducted a meta-analysis to examine the impact of patient navigation on the time to diagnostic Figure 1 . Effects of intervention and comorbidities on the time to diagnostic resolution: unadjusted time-to-event curves for patients with CCI scores of 0, 1, and >1 stratified by navigation and control arm. In the control arm, the time to diagnostic resolution was longer with an increasing comorbidity score. For each level of comorbidity, the time to diagnostic resolution was earlier in the navigated arm versus the control arm. CCI indicates Charlson Comorbidity Index. (20) 683 (22) 598 (19) resolution. The models included comorbidities as 2 dummy variables and an interaction term for patient navigation and the number of comorbidities. We then combined the effect size for each level of comorbidity across the 9 cancer types and clinical sites. Persons with a CCI score > 1 experienced significant delays in the diagnostic resolution of an abnormal finding on cancer screening in comparison with those without comorbidities. None of the interaction terms were significant, and this indicated that navigation was not differentially effective according to the level of comorbidities that patients had.
The results of the analysis for the 90-day time period showed no differences in the odds of achieving diagnostic resolution for patients with CCI scores of 1 or > 1 in comparison with patients with no comorbidities. However, at the end of 1 year, the results of the meta-analysis indicated that patients with CCI scores > 1 were less likely to achieve resolution of their abnormal findings than patients with no comorbidities (combined adjusted odds ratio, 0.722; 95% CI, 0.556-0.938). An influence analysis of these data was performed, and the results demonstrated that the removal of the colorectal data resulted in a nonsignificant combined result (adjusted odds ratio, 0.782; 95% CI, 0.593-1.033). Table 2 provides the results of the subgroup analysis of the pooled data; the control group with no comorbidity was used as the reference. In this adjusted analysis, patients with CCI scores > 1 had a significant delay (aHR, 0.78; 95% CI, 0.67-0.91) in comparison with patients with no comorbidity. Those with navigation had a more timely diagnostic resolution for each CCI score level. The time to diagnostic resolution for the navigated patients with no comorbidity had an aHR of 1.11 (95% CI, 1.04-1.19). For navigated patients with a CCI score of 1, the aHR was 1.16 (95% CI, 1.04-1.30); this indicated that these groups reached diagnostic resolution more quickly than the control group with no comorbidities. For navigated patients with a CCI score 2, the aHR was 0.99 (95% CI, 0.86-1.17); this eliminated the delays in diagnostic care in comparison with control patients with no comorbidities. Program sites (a,d,f,g ) and cancer sites, includes the combined result and reports a metaanalysis of the adjusted hazard ratio of the time to resolution of an abnormal screening result for each level of comorbidity. An adjusted hazard ratio less than 1 indicates a detrimental effect of the presence of comorbidities. CCI indicates Charlson Comorbidity Index. 
DISCUSSION
The goal of our study was to explore the effects of comorbidities and patient navigation on the time to diagnostic resolution after an abnormal cancer screening. The results of this study demonstrated that having more severe comorbidities delayed the time to diagnostic resolution in comparison with having either no or less severe comorbidities. In addition, patients with more severe comorbidities (ie, those with CCI scores 2) who did not achieve diagnostic resolution within 90 days were less likely to achieve diagnostic resolution within 1 year. Our second main finding was that patients with navigation had reduced times to diagnostic resolution at all levels of comorbidities, and for patients with more severe comorbidities, navigation reduced disparities in timely care.
For patients with more severe or multiple comorbidities, there are a number of reasons that diagnostic care would be delayed. One may be the stabilization of other medical conditions before more advanced diagnostic testing, especially colonoscopy or biopsy, can be performed. This stabilization of care often requires additional coordination among specialists, added office visits, and possibly other tests or procedures, all of which can add to the time to final diagnostic testing and may be insensitive to patient navigation. However, this additional coordination of care can also result in new opportunities of missed appointments and other delays due to barriers to care that are addressable through patient navigation. A number of studies have shown that patients with comorbidities have delays in cancer screening, diagnosis, and time to treatment, [21] [22] [23] [24] with some studies showing that these delays are associated with the upstaging of cancer by the time of surgical treatment. 25 Our study results demonstrated that patient navigation had a positive effect on timely diagnostic care for patients with reported comorbidities. Navigation was effective in reducing delays in diagnostic resolution among those with more severe comorbidities (CCI score > 1), who had the longest delays in care. Because patient navigation was developed to improve coordination of care, patient navigation may be particularly effective for patients with comorbidities. A patient navigator may be specifically able to coordinate care across multiple specialties, ensure that appropriate clinical information is available to providers, and thus reduce delays and gaps in care.
This study has several strengths, including a large, diverse population of participants and the availability of CCI data from 4 sites. This study was also able to demonstrate that comorbidities were not a proxy for other barriers to care, such as transportation or health insurance.
Limitations of the study include the heterogeneity of the study design and analyses across PNRP sites, including several methods for collecting comorbidity data. To address this heterogeneity, we determined a separate aHR for each site and each cancer type, and then we pooled these with a meta-analysis random effects methodology with a sensitivity analysis to ensure no undue influence of findings from 1 site. This methodology 26 demonstrated that the effect of comorbidities on the timely completion of care was seen broadly across most sites and screening tests and was not related to the study design. Another limitation is that most of the data reflect care for women with breast or cervical cancer screening abnormalities, and they may not be generalizable to men or other cancer screenings.
In conclusion, as patient navigation becomes the standard of care for diagnostic and therapeutic cancer management, there is a need for sites to determine which patients are at highest risk for delays and which patients will benefit most from the patient-navigation intervention. 27 These findings are important for providers to consider when they are ordering diagnostic tests after abnormal cancer screening for patients with multiple chronic diseases. Patients with comorbidities are more likely to have delays in their diagnostic care. Therefore, additional resources, including patient navigation with tracking to the completion of diagnostic resolution, are indicated for this population to address and prevent additional delays in care.
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